# EDGAR Filing Document

**Accession Number:** 0001875091
**File Stem:** 0001213900-23-021268
**Filing Date:** 2023-3
**Character Count:** 18163
**Document Hash:** 86c504538c6bf96e9981bd3d54783761
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-021268.hdr.sgml**: 20230320

**ACCESSION NUMBER**: 0001213900-23-021268

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 29

**CONFORMED PERIOD OF REPORT**: 20230320

**FILED AS OF DATE**: 20230320

**DATE AS OF CHANGE**: 20230320

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NeuroSense Therapeutics Ltd.
- **CENTRAL INDEX KEY:** 0001875091
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41084
- **FILM NUMBER:** 23745145

**BUSINESS ADDRESS:**
- **STREET 1:** 11 HAMENOFIM ST.
- **STREET 2:** BUILDING B
- **CITY:** HERZLIYA
- **STATE:** L3
- **ZIP:** 4672562
- **BUSINESS PHONE:** 972-9-9531142

**MAIL ADDRESS:**
- **STREET 1:** 11 HAMENOFIM ST.
- **STREET 2:** BUILDING B
- **CITY:** HERZLIYA
- **STATE:** L3
- **ZIP:** 4672562

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of March 2023

Commission File Number: 001-41084

**NeuroSense Therapeutics Ltd.**

(Translation of registrant's name into English)

**11 HaMenofim Street, Building B<br> Herzliya 4672562 Israel<br> +972-9-799-6183**<br> (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

NeuroSense Therapeutics Ltd. (the "Company") has made available a presentation about its business (the "Presentation"), a copy of which is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information contained in the Presentation is summary information that should be considered in the context of the Company's filings with the Securities and Exchange Commission and other public announcements the Company may make by press release or otherwise from time to time.

**Exhibit Index**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Presentation, dated March 2023](ea175484ex99-1_neurosense.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **NeuroSense Therapeutics Ltd.** | **NeuroSense Therapeutics Ltd.** |
| Date: March 20, 2023 | By: | /s/ Alon Ben-Noon |
|  |  | Alon Ben-Noon |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

Corporate Presentation March 2023 Nasdaq: NRSN

![](ex99-1_002.jpg)

Disclaimer This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" withi n the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. Al l s tatements contained in this presentation other than statements of historical facts, including our business strategy and plans and objec tiv es for future operations, including our financial performance, are forward looking statements. The words " anticipate"," believe," " con tinue," "estimate," "expect," "intend," "may," "will" and similar expressions are intended to identify forward looking statements. We ha ve based these forward looking statements largely on our current expectations and projections about future events and trends that we b eli eve may affect our financial condition, results of operations, business strategy, short term and long term business operations an d objectives, and financial needs. Forward looking statements made in this presentation include statements about the timing of reporting top - line results from our ALS Phase 2b clinical trial, market for therapeutics targeting neurodegenerative diseases and its opportunities for our product c and idates; our expectations regarding our competitive advantages; the planned development timeline of our product candidates; and characterizations of the pre - clinical and clinical trial results of our product candidates. Forward looking statements are subje ct to a number of risks and uncertainties and represent our views as of the date of the presentation, including a delay in the report ing of top - line results from our ALS Phase 2b clinical trial and a delay in other clinical and regulatory milestones . The future events an d trends discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. You should not rely on these statements as representing our views in the future. More info rma tion about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Annual Report on Fo rm 20 - F filed with the Securities and Exchange Commission on April 14, 2022. We undertake no obligation or duty to update informati on contained in these forward looking statements, whether as a result of new information, future events or otherwise. Trademarks in this presentation are the property of their respective owners and used for informational and educational purpos es only.

![](ex99-1_003.jpg)

NeuroSense is a Leader in Developing Novel Combination Therapies for ALS and Other Neurodegenerative Diseases ALS Alzheimer Parkinson Topline data from Phase 2 b placebo - controlled clinical trial expected in H 2 2023 Commencement of Phase 1 / 2 placebo - controlled clinical trial expected in H 1 2023 Complete Biomarker Studies expected in H 1 2023 Discovery Pre - clinical Phase 1 Phase 2 Phase 3 NDA Indication Next Milestone Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_004.jpg)

Treatment options for ALS is a dire unmet need with only three FDA approved drugs available : Riluzole , Edaravone , & Relyvrio All w ith a mild therapeutic effect ~ 24 % Growth in Patients by 2040 in the US and EU (2) > 80,000 ALS Patients in NeuroSense ' s planned target market (2) + 5,000 New cases of ALS each y ear (US) (1) Annual Market) 3 (Opportunity ~ $3 B 1. ALS - Amyotrophic Lateral Sclerosis, Johns Hopkins Medicine 2. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040 , Nature Communications, 2016 3. Management estimate ALS is an incurable neurodegenerative disease, causing complete paralysis and ultimately death within 2 - 5 years from diagnosis Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_005.jpg)

PrimeC: Value Proposition Novel combination therapy designed to address multiple disease targets in a synergistic manner Promising efficacy signals observed from ALS Phase 2 a clinical trial ALS Phase 2 b top - line results from placebo - controlled clinical trial expected in H 2 2023 Patent coverage for novel formulation, method, & combination (until 2038) Expedited regulatory pathway (orphan drug designation / 505 (b) 2 pathway) Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_006.jpg)

PrimeC: Two Compounds One Potentially Powerful Outcome Celecoxib - an NSAID which reduces: • N euroinflammation • G lutamate excitotoxicity • O xidative stress Ciprofloxacin - a fluoroquinolone which regulates: • microRNA synthesis • Iron accumulation PrimeC is a novel formulation , consisting of specific doses of two FDA - approved drugs, designed to work synergistically on more than one target in ALS Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro PrimeC ' s effect on pathways which lead to neuron death in ALS

![](ex99-1_007.jpg)

Potential of Combined Therapy Current Strategies: Synergistic MOAs OR Improved PK Alzheimer Donepezil + Memantine Parkinson Entacapone + levodopa/carbidopa ALS Sodium Phenybuterate + Taurursodiol SMA Onasemnogene + Nusinersen Epilepsy Lamotrigine + Valproate/Carbamazepine Successful combination strategies in neurology: Case Study: Amylyx (NASDAQ: AMLX) Market Cap: $2.65 B (January 2023) Drug: ALS Combination Therapy of generic + supplement Price: $158,000 / year Estimated 2026 Sales: $1.1 B/ year\* The FDA approved Amylyx ' s drug, Relyvrio , in September 2022 after Phase 2 clinical trial attenuated diseases progression (ALSFRSr) by 25 % when compared to placebo Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_008.jpg)

PrimeC is a Combination Therapy Leveraging BOTH Strategies And Synergistic MOA MOA Targeting Multiple Disease Pathways Simultaneously to Combat Complex Disease Improved PK Formulation Synchronized Pharmacokinetic Profile to Enhance Efficacy Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_009.jpg)

Improved Pharmacokinetic (PK) Profile PK proof of concept studies in rodents This finding is attributed to Celecoxib blocking exit of Ciprofloxacin in the neuron PrimeC ' s combination (Celecoxib + Ciprofloxacin) remained at a higher concentration in rodent brain tissue for longer , when compared to administration of Ciprofloxacin alone Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro C iprofloxacin Ciprofloxacin + Celecoxib

![](ex99-1_010.jpg)

PrimeC ' s Formulation Induces a Synchronized PK Profile A s ynchronized PK profile of the two compounds, potentially maximizes the synergy between them PK profile studies in humans Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro Synchronized concentration peak

![](ex99-1_011.jpg)

Synergistic MOA Motor Neuron Nucleus Cytoplasm PrimeC ' s targets multiple pathways which lead to neuronal death in ALS Intracellular • MicroRNA dysregulation • TDP - 43 aggregation • Cellular recycl ing processes Extracellular • Neuroinflammation • Oxidative Stress Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_012.jpg)

PrimeC Demonstrated a Neuroprotective Effect in ALS Zebrafish Models PrimeC Results in Zebrafish , a Key Animal Model for ALS (widely accepted model) ' Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis ' Annals of Clinical and Translational Neurology , 2020 Improvement in motor p erformance , via measurement of distance swam Fish Swimming Pattern in a Well Healthy ALS ALS + PrimeC Control Celecoxib Ciprofloxin Riluzole PrimeC Recovery of Motor Neuron Morphology Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_013.jpg)

PrimeC Phase 2 a Trial Design NST 002 15 patients Open - Label Intermediate formulation of PrimeC 12 - month dosing Clinic visit every 3 months Phone visit every 1.5 months Location: Tel Aviv Sourasky Medical Center Safety Blood test, electrocardiogram (ECG), urea, vital signs, adverse events (AE) Efficacy ALSFRSr - Revised ALS Functional Rating Scale – 0 - 48 FVC - Forced Vital Capacity Biomarkers Examination of key elements for ALS diagnosis as well as PrimeC mechanism of action 3 1 PrimeC PrimeC Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro 2

![](ex99-1_014.jpg)

Phase 2 a 12 - Month Data: PrimeC Improved Respiratory Function Decline & Attenuated Disease Progression\* ALSFRSr Score Forced vital capacity (FVC%) \*\*In comparison to PRO - ACT matched - control : P ooled R esource O pen - A ccess ALS C linical T rials D atabase \* " Combination of ciprofloxacin/ celecoxib as a novel therapeutic strategy for ALS " Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration , 2022 PrimeC attenuated disease progression, ALSFRSr by 18 % \*\* PrimeC slowed respiratory function decline, FVC by 30 % \*\* 18 % 30 % PrimeC PrimeC Pro - ACT Pro - ACT Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_015.jpg)

Phase 2 a Biomarker Study Design Service provided by: Stage II Longitudinal non - treated study The natural course of ALS was examined longitudinally over 12 months compared to an indirect placebo control group Stage I Case study experiment Cross - sectional comparison of ALS and healthy - control serves as baseline Stage III NST 002 clinical study The effect of PrimeC on selected biomarkers was tested in samples from an open - label Phase 2 a study Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_016.jpg)

PrimeC Significantly Altered Key ALS Biomarkers Treated: Patients from NST 002 Phase 2 a clinical trial who received PrimeC (intermediate formulation) Non - treated: Matched patients on standard of care Neuroinflammation TDP - 43 Accumulation PrimeC PrimeC Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_017.jpg)

Phase 2 a Trial with PrimeC : Met Primary Endpoints & Exploratory Endpoints Positive Clinical Signal Observed These results led NeuroSense to commence a Phase 2 b clinical study, using an improved new extended - release formulation of PrimeC Significant changes in ALS - related biomarkers Well tolerated, no drug related SAEs Reduced functional and respiratory deterioration Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_018.jpg)

PrimeC Phase 2 b Trial Design Randomized, Prospective, Double - Blind, Placebo - Controlled Study Using PrimeC ' s novel extended - release formulation NST 003 69 patients 2:1 PrimeC to Placebo New formulation of PrimeC 6 - month double blind 12 - month open label extension Clinic visit every 2 months Locations: Canada, Italy, & Israel Primary Efficacy Biomarkers TDP - 43 Prostagladin 2 Secondary Efficacy Clinical Outcomes ALSFRSr SVC Survival Safety & Tolerability Adverse Events Vital Signs ECG Clinical Lab Evaluations 1 3 PrimeC PrimeC Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro 2

![](ex99-1_019.jpg)

Intellectual Property Overview Our patents Methods for Treating ALS using Combinations of Celecoxib and Ciprofloxacin Compositions comprising an anti - inflammatory drug and a dicer activator for use in the treatment of neuronal diseases Methods for Treating neurodegenerative disorders using Combinations of Celecoxib and Ciprofloxacin Composition Comprising Ciprofloxacin and Celecoxib 1 2 3 4 Granted: US Granted: Australia, Canada Allowed: European Patent Office Pending: Japan, Israel Pending: US Provisional: USPTO Expiry date: June 2038 Expiry date: June 2038 Expiry date: June 2038 Expiry date: Oct 2042 Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_020.jpg)

Key Collaborations Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_021.jpg)

Milestones Achieved & Upcoming Potential Catalysts Expected ALS End of Phase 2 FDA meeting Expect to initiate ALS Phase 3 clinical trial Expected Alzheimer Phase 2 trial results ALS Phase 2 b PARADIGM study initiated FDA IND Clearance for PrimeC PK study single - dose & multi - dose completed successfully In - life 90 - day GLP toxicology study completed successfully 2022 2023 2024 Completed Alzheimer ' s biomarker study with positive results Parkinson biomarker study results Expect to initiate Alzheimer Phase 2 trial Expected ALS Phase 2 b clinical trial top - line results ALS Alzheimer Parkinson Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_022.jpg)

VP of R& D Shiran Zimri, PhD CMO Ferenc Tracik , MD Founder & CEO Alon Ben - Noon Chairman of the Board Mark Leuchtenberger CFO Or Eisenberg Niva Russek - Blum, PhD VP Discovery & IP Generator VP of BD Nedira Salzman VP of Regulatory Affairs Diana Shtossel Experienced Leadership Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_023.jpg)

Senior VP at the Barrow Neurological Institute Chair of the Department of Neurology Prof. Jeremy Shefner (Chair) Dr. Jinsy Andrews Associate Professor of Neurology, Division of Neuromuscular Medicine, Columbia University Director of Neuromuscular Clinical Trials Prof. Merit Cudkowicz Chief of Neurology at Mass General and Director, Sean M. Healey & AMG Center for ALS Professor of Neurology at Harvard Medical School Prof. Jeffrey Rosenfeld Professor of Neurology and Associate Chairman of Neurology at Loma Linda University School of Medicine Medical Director of Center for Restorative Neurology at Loma Linda University Prof. Orla Hardiman Head of Academic Unit of Neurology at Trinity College Dublin and Consultant Neurologist at Beaumont Co - Chair of the European Consortium to Cure ALS and Chair of the Scientific Committee of ENCALS Scientific Advisory Board Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_024.jpg)

Read more about us! Learn more: NeuroSense YouTube Channel Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_025.jpg)

Equity Overview – Feb. 28 , 2023 Nasdaq: NRSN Price: $1.86 52 - Week Range: $1.08 - $8.18 Shares Outstanding: ~ 11.7 M Share on a fully diluted basis: ~ 15 M Market Cap: ~$22 M Cash Balance (9 / 30 / 22): ~$8.4 M Avg. Daily Trading Volume (90 day): ~ 1.5 M Analyst Coverage: Maxim Group No Debt Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_026.jpg)

NRSN Highlights Summary Novel combination therapy designed to address multiple disease targets in a synergistic manner Promising efficacy signals observed from ALS Phase 2 a clinical trial Statistically significant biomarker data in Phase 2 a clinical trial which correlated to clinical signals observed Expedited regulatory pathway - orphan drug designation & 505 (b) 2 Top - line results from ALS Phase 2 b placebo - controlled clinical trial expected in H 2 2023 Funded through Q 4 2023 Strong pipeline with several upcoming catalysts Summary Phase 2 b Phase 2 a Results Pre - clinical PrimeC Intro

![](ex99-1_027.jpg)

Nasdaq: NRSN Thank you! Thank You For more information: info@neurosense - tx.com